6Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes:meta-analysis of randomized controlled trials[J]. BMJ, 2002,324:1.
7Retnakaran R, Hochman J, DeVries JH, et al. Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections: The impact of baseline AIc[J]. Diabetes Care,2004,27(11) :2590.
8Raskin P, Bode BW, Marks BJ, et al. Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: A randomized, parallel- group, 24-week study[J]. Diabetes Care, 2003,26(9):2598.
9Jill WB,Jeanne AL. Insulin pump therapy: A meta-analysis[J].Diabetes Care,2003,26(4):1079.
10Jennings AM, Lewis KS, Murdoch S, et al. Randomized trial comparing continuous subcutaneous insulin infusion and conventional insulin therapy in type Ⅱ diabetic patients poorly controlled with sulfonylureas[J]. Diabetes Care, 1991,14:738.
二级参考文献41
1Lee Y-C,Simamora P ,Pinsuwan S, et al. Review on the systemic delivery of insulin via the ocular route. Int J Pharm,2002,233:1.
2Nishihata T, Rytting J H. Absorption-promoting adjuvants :enhancing action on rectal absorption. Adv Drug Deliv Rev, 1997,28 : 205.
3CN 1335182 A 13.
4William A, Blair A,Thomas W, et al. Intranasal biovailability of insulin powder formulations effect of permeation enhancer-to protein ratio. J Pharm Sci,1991,80(8) :725.
5Bj o k E, Edman P. Degradable starch microspheres as a nasal drug delivery system for insulin. Int J Pharm, 1988,47 : 233.
6Takenaga M,Serizawa Y,Azeeiu Y, et al. Mieropartieae resins as a protential nasal drug delivery system for insulin. J Control Rel,1998,52(1-2):81.
7Chiou G C Y,Chuang C Y. Improvement of systemic absorption of insulin through eyes with absorption enhancers. J Pharm Sci, 1989,78:815.
8Simamora P,Lee Y-C,Yalkowsky SH. Ocular device for the controlled systemic delivery of insulin. J Pharm Sci, 1996,85 : 1128.
9Lee Y-C,Simamora P, Yalkowsky S H. Effect of Brij-78 on systemic delivery of insulin from an oculardevice. J Pharm Sci, 1997,86(4):430.
10Lee Y-C, Yalkowsky SH. Effect of formulation on the systemic absorption of insulin from enhancer-free ocular device. Int J Pharm,1999,85:199.
9HASAN H.Shorten intensified therapy of newly diagnosed T2DM with an insulin pump can improved glycocmic control.Diabetes Care,1997,20(9):1353-1355.
10Imagawa A,Hanafusa T,Miyagewa J,et al.A novel subtype of type 1 diabetes mellitns characterized by a rapid onset and absence of diabetes-related antibodies.N EngJ Med,2000,342:301-307.
